BioCryst Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the recipient of unusually large options trading on Monday. Stock traders bought 2,478 call options on the stock. This represents an increase of approximately 59% compared to the average volume of 1,554 call options.

Analyst Ratings Changes

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.83.

Institutional Trading of BioCryst Pharmaceuticals

Several large investors have recently bought and sold shares of BCRX. Bank of New York Mellon Corp boosted its position in BioCryst Pharmaceuticals by 1.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 767,571 shares of the biotechnology company’s stock valued at $5,434,000 after acquiring an additional 8,087 shares in the last quarter. Arete Wealth Advisors LLC boosted its position in BioCryst Pharmaceuticals by 64.7% during the 3rd quarter. Arete Wealth Advisors LLC now owns 23,300 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 9,150 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of BioCryst Pharmaceuticals by 96.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 2,388 shares during the last quarter. Fifth Third Bancorp lifted its holdings in shares of BioCryst Pharmaceuticals by 17,500.0% during the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,500 shares during the last quarter. Finally, Panagora Asset Management Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 6.1% during the third quarter. Panagora Asset Management Inc. now owns 727,480 shares of the biotechnology company’s stock valued at $5,151,000 after purchasing an additional 41,971 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX traded up $0.85 during trading hours on Monday, hitting $5.30. The company’s stock had a trading volume of 5,657,902 shares, compared to its average volume of 3,322,742. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -4.36 and a beta of 1.96. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $8.96. The business has a 50-day simple moving average of $4.93 and a 200-day simple moving average of $5.46.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The company had revenue of $93.40 million during the quarter, compared to the consensus estimate of $89.19 million. On average, equities research analysts forecast that BioCryst Pharmaceuticals will post -0.69 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.